GlaxoSmithKline plc (GSK.L)
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
Company Info
Highlights
£57.84B
£0.76
18.76
0.38
£31.53B
£22.58B
£8.24B
£1,227.88 - £1,711.35
£1,671.58
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
GlaxoSmithKline plc (GSK.L) returned 8.33% year-to-date (YTD) and -16.09% over the past 12 months. Over the past 10 years, GSK.L returned 4.85% annually, underperforming the S&P 500 benchmark at 10.68%.
GSK.L
8.33%
3.85%
8.33%
-16.09%
-3.62%
1.27%
4.85%
^GSPC (Benchmark)
-1.34%
5.02%
-3.08%
9.39%
13.76%
14.45%
10.68%
Monthly Returns
The table below presents the monthly returns of GSK.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4.34% | 5.55% | -0.31% | 1.47% | -2.77% | 8.33% | |||||||
| 2024 | 8.12% | 7.19% | 2.64% | -2.08% | 6.47% | -13.42% | -1.14% | 10.63% | -8.48% | -8.18% | -3.06% | 0.86% | -3.51% |
| 2023 | -0.99% | 1.08% | 0.25% | 0.84% | -5.65% | 3.15% | -0.30% | 1.34% | 7.43% | -2.32% | -1.62% | 2.17% | 4.94% |
| 2022 | 2.27% | -4.54% | 6.59% | 9.09% | -2.82% | 1.90% | -3.13% | -19.23% | -5.34% | 9.42% | -0.54% | 2.19% | -7.40% |
| 2021 | 1.12% | -10.64% | 8.16% | 4.01% | 1.76% | 5.59% | -0.11% | 4.42% | -3.99% | 7.48% | 2.33% | 5.35% | 26.74% |
| 2020 | 0.28% | -11.22% | -3.05% | 9.67% | 1.76% | -2.11% | -6.53% | -2.63% | -1.36% | -11.03% | 7.44% | -2.04% | -20.72% |
| 2019 | -0.94% | 2.87% | 6.64% | -1.47% | -1.73% | 3.25% | 7.99% | 1.69% | 1.93% | 1.38% | 0.27% | 1.43% | 25.38% |
| 2018 | -0.16% | 0.75% | 6.64% | 4.84% | 5.64% | 0.38% | 3.39% | -0.16% | -1.51% | -1.67% | 8.64% | -8.04% | 19.09% |
| 2017 | -2.18% | 9.37% | 0.70% | -6.60% | 11.20% | -3.99% | -7.40% | 2.55% | -2.93% | -8.80% | -4.41% | 3.36% | -10.77% |
| 2016 | 4.81% | -1.36% | 0.89% | 3.33% | 0.33% | 11.04% | 5.20% | -1.80% | 0.24% | -1.49% | -6.49% | 4.45% | 19.63% |
| 2015 | 6.61% | 6.66% | 0.29% | -2.04% | -2.75% | -9.01% | 5.56% | -2.67% | -5.56% | 10.98% | -2.16% | 1.29% | 5.48% |
| 2014 | -2.95% | 8.35% | -4.79% | 2.54% | -0.75% | -2.31% | -8.15% | 4.01% | -4.17% | 0.32% | 6.17% | -7.34% | -10.06% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GSK.L is 19, meaning it’s performing worse than 81% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
GlaxoSmithKline plc provided a 4.35% dividend yield over the last twelve months, with an annual payout of £0.62 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | £0.62 | £0.61 | £0.56 | £0.67 | £0.81 | £0.81 | £0.81 | £0.81 | £0.81 | £0.78 | £0.81 | £0.81 |
Dividend yield | 4.35% | 4.53% | 3.84% | 4.69% | 4.98% | 5.96% | 4.50% | 5.36% | 6.05% | 4.93% | 5.83% | 5.81% |
Monthly Dividends
The table displays the monthly dividend distributions for GlaxoSmithKline plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | £0.00 | £0.16 | £0.00 | £0.00 | £0.16 | £0.32 | |||||||
| 2024 | £0.00 | £0.16 | £0.00 | £0.00 | £0.15 | £0.00 | £0.00 | £0.15 | £0.00 | £0.00 | £0.15 | £0.00 | £0.61 |
| 2023 | £0.00 | £0.14 | £0.00 | £0.00 | £0.14 | £0.00 | £0.00 | £0.14 | £0.00 | £0.00 | £0.14 | £0.00 | £0.56 |
| 2022 | £0.00 | £0.23 | £0.00 | £0.00 | £0.14 | £0.00 | £0.00 | £0.16 | £0.00 | £0.00 | £0.14 | £0.00 | £0.67 |
| 2021 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
| 2020 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
| 2019 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
| 2018 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
| 2017 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
| 2016 | £0.00 | £0.20 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.78 |
| 2015 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
| 2014 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.81 |
Dividend Yield & Payout
Dividend Yield
GlaxoSmithKline plc has a dividend yield of 4.35%, which is quite average when compared to the overall market.
Payout Ratio
GlaxoSmithKline plc has a payout ratio of 0.38%, which is below the market average. This means GlaxoSmithKline plc returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the GlaxoSmithKline plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GlaxoSmithKline plc was 51.33%, occurring on Mar 12, 2003. Recovery took 2209 trading sessions.
The current GlaxoSmithKline plc drawdown is 17.17%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -51.33% | Jan 11, 1999 | 1053 | Mar 12, 2003 | 2209 | Dec 6, 2011 | 3262 |
| -42.99% | Jan 14, 1992 | 395 | Aug 13, 1993 | 554 | Oct 23, 1995 | 949 |
| -30.96% | Jan 20, 2020 | 282 | Feb 26, 2021 | 223 | Jan 17, 2022 | 505 |
| -27.99% | Jul 5, 2022 | 56 | Sep 22, 2022 | 368 | Mar 7, 2024 | 424 |
| -27.42% | May 16, 2024 | 230 | Apr 9, 2025 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of GlaxoSmithKline plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of GlaxoSmithKline plc, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 13.2% positive surprise.
Valuation
The Valuation section provides an overview of how GlaxoSmithKline plc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for GSK.L, comparing it with other companies in the Drug Manufacturers - General industry. Currently, GSK.L has a P/E ratio of 18.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for GSK.L compared to other companies in the Drug Manufacturers - General industry. GSK.L currently has a PEG ratio of 0.4. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GSK.L relative to other companies in the Drug Manufacturers - General industry. Currently, GSK.L has a P/S ratio of 1.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GSK.L in comparison with other companies in the Drug Manufacturers - General industry. Currently, GSK.L has a P/B value of 4.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |